SFL Missions Inc. Announces Launch and Successful Deployment of Two GHGSat Greenhouse Gas Monitoring Microsatellites
TORONTO — SFL Missions Inc. today announced the successful launch and deployment of the GHGSat-C12 and GHGSat-C13 (also known as Pierre and Valmay, respectively) greenhouse gas monitoring microsatellites developed for GHGSat of Montreal. SFL Missions Inc. developed the satellites on a low-cost, high-performance 15-kg NEMO bus, the same used to build the first nine GHGSat spacecraft.
Article content
GHGSat-C12 and -C13 launched on June 23 from Vandenberg Space Force Base, California, aboard the SpaceX Transporter 14 ride-share mission. Ground control has established communications with both spacecraft.
Article content
'SFL Missions is pleased that GHGSat has once again placed trust in us to support development of its industry-leading commercial greenhouse gas monitoring constellation,' said SFL Missions Director Dr. Robert E. Zee. 'We take pride in developing barrier-breaking, budget-aggressive small satellite missions for commercial, government, and academic customers worldwide.'
Article content
GHGSat is the world leader in emissions monitoring technologies and pioneered the first satellite capable of detecting and measuring facility-level greenhouse gas emissions from space. Decision-makers across governments and industries including oil and gas, power generation, mining, waste management, and agriculture rely on GHGSat emissions data to drive emissions reduction and accelerate the decarbonization of the planet.
Article content
SFL Missions was selected to develop the two latest satellites due in part to the precise attitude control and target tracking capabilities of its satellite platforms – rare among spacecraft of their size and price points. This enables exact pointing of the onboard sensors, which is vital to the accurate detection and measurement of greenhouse gas emissions from sources on the ground. SFL Missions' platforms have earned a well-deserved reputation for quality, performance and reliability.
Article content
In addition, SFL Missions incorporates robust design margins into every satellite, and these include the onboard power systems, data storage, and downlink capacities. These margins in orbit translate into better operations and longer missions, contributing to the better-than-anticipated collection capacity that GHGSat has achieved with its earlier NEMO-based spacecraft.
Article content
SFL Missions is building on a heritage that has produced 88 operationally successful missions and 380+ cumulative years in orbit. The firm is developing nano-, micro-, and small satellites and constellations using space-proven bus designs from 3 to 500 kilograms for Earth observation, communications, environmental monitoring, maritime situational awareness, space astronomy, scientific research and more.
Article content
Currently expanding its Toronto satellite manufacturing facilities, SFL Missions has 20 satellites under development or awaiting launch. In addition, SFL Missions offers a Flex Production program that will give customers the option of having satellites developed in their own location, at a third-party site, or at the SFL Missions facility.
Article content
SFL Missions Inc. generates bigger returns from smaller, lower cost satellites. Small satellites built by SFL Missions consistently push the performance envelope and disrupt the traditional cost paradigm. We build quality small satellites at low cost that work the first time and enable NewSpace companies to mass produce through our Flex Production program. Satellites are built with advanced power systems, stringent attitude control and high-volume data capacity that are striking relative to the budget. We arrange launches globally and maintain a mission control center accessing ground stations worldwide. The pioneering and barrier-breaking work of SFL Missions is a key enabler to tomorrow's cost-aggressive satellites and constellations.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
4 hours ago
- National Post
Cellulotech Secures Strategic Investment to Scale Its Breakthrough Green Chemistry Technology
Article content VICTORIA, British Columbia — Cellulotech, a pioneering company in green chemistry and sustainable material innovation, is proud to announce the successful closing of a seed fundraising round led by Neglected Climate Opportunities, a subsidiary of the Jeremy and Hannelore Grantham Environmental Trust. The Round also welcomed the participation of Meliorate Partners, a leading early-stage sustainability fund focusing on transformative industrial innovators. Article content This strategic investment will empower Cellulotech to scale its patented solvent-free cellulose functionalization technology—enabling the replacement of plastic, PFAS, and other unsustainable or harmful materials. The innovation offers a scalable, bio-based, cost-effective, and fully recyclable cellulose-based alternative —including applications in paper, packaging, hygiene, textiles, or construction—unlocking a significant opportunity to competitively decarbonize and detoxify global supply chains and add value to the most abundant organic compound on earth: cellulose. Article content 'We're excited to join forces with investors who not only have decades of experience scaling breakthrough technologies but also share our ambitious, long‑term vision,' said Romain Metivet, Co‑Founder and CEO of Cellulotech. Article content 'Their support recognizes my discovery, and nothing is more exciting than seeing it finally reach the market,' added Dr. Daniel Samain, Co‑Founder and Scientific Director. As regulatory and market pressures accelerate the shift to sustainable alternatives, Cellulotech is leading the way—delivering green technologies that not only meet standards but carry a clear 'green discount,' making sustainability the default—without compromising performance or cost. Article content Article content Article content Article content Name: Article content Romain Metivet Article content Article content Title: Article content Co‑Founder & CEO Article content Article content Phone: Article content +1 604 902 1405 Article content Article content Article content Article content
Globe and Mail
4 hours ago
- Globe and Mail
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent survival benefit compared to standard-of-care chemotherapy in randomized studies in the large HR+/HER2- metastatic breast cancer indication Data from over 1,100 patients across tumor types reveals a favorable, well-understood safety profile SAN DIEGO and CALGARY, AB , July 8, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced a strategic update highlighting its compelling clinical data from two tumor types and outlining a sharpened focus on advancing pelareorep, the Company's intravenously delivered oncolytic virus immunotherapy, into registration-enabling studies. "We are no longer in the business of funding proof-of-concept studies," said Jared Kelly , Chief Executive Officer of Oncolytics. "We have meaningful clinical data in hand—not just signals. The survival benefit across multiple tumor types demands a focused approach to take pelareorep directly into registration-enabling trials. We will use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology." Results from two completed first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) trials demonstrate a strong and consistent efficacy signal showing extremely rare 2-year overall survival rates of 21.9% vs. 9.2% based on pooled data from over 100 patients across two studies evaluating pelareorep combined with a chemotherapy backbone. In addition, a best-in-class 62% objective response rate (ORR) was observed in a single-arm study of pelareorep in combination with a chemotherapy backbone and a checkpoint inhibitor in 13 evaluable patients. These results collectively represent promising efficacy for a therapeutic regimen that includes an immunotherapy in this difficult-to-treat cancer. Currently, there are no approved immunotherapies for first-line treatment of mPDAC. Pelareorep's clinical activity in HR+/HER2- metastatic breast cancer – a large indication with continued significant unmet medical need and no currently approved immunotherapies – has been demonstrated in two randomized phase 2 studies, both of which showed a median overall survival (mOS) benefit of greater than 10 months compared to standard-of-care chemotherapy (IND.213 mOS: 21.0 vs. 10.8 months; BRACELET-1 mOS: not statistically reached; conservative estimate = 32.1 months vs. 18.2 months). In the randomized, controlled BRACELET-1 study, pelareorep combined with paclitaxel yielded a 12.1-month median progression-free survival (PFS) compared to 6.4 months in the paclitaxel alone control arm. "Pelareorep represents a tipping point for immunotherapy in cold tumors," said Dr. Thomas Heineman , Chief Medical Officer of Oncolytics. "It is delivering consistent immunologic and clinical responses in multiple tumor types. Most impressively, pelareorep activates the immune system to produce clinical benefits in cancers that are typically unresponsive to immunotherapies like mPDAC and unresectable HR+/HER2- breast cancer, creating new oncology entry points for immune-based combination therapies." Data from more than 1,100 patients enrolled in multiple studies across several tumor types affirm that pelareorep has a favorable, well-understood safety profile. The most common treatment-related adverse events (TRAEs) are "flu-like" symptoms, such as fever, chills, headache, fatigue, myalgia, cough, anorexia, nausea, diarrhea, or vomiting, and rarely resulted in clinically significant grade ≥3 TRAEs. Adverse events are typically transient and manageable with over-the-counter medications. Pelareorep received Fast Track designations from the U.S. Food and Drug Administration (FDA) in 2017 for metastatic breast cancer and in 2022 for mPDAC in combination with chemotherapy and atezolizumab. In 2015, pelareorep also received Orphan Drug Designations from the FDA and European Medicines Agency (EMA) for the treatment of pancreatic cancer. The Company released a new corporate presentation, available on its website, that provides detailed clinical and translational data. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our focus on advancing pelareorep directly into registration-enabling trials; our plans to use our fast-track status to find the most efficient regulatory path forward this summer to advance our platform in a product technology; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication jpatton@ Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@ Media Contact for Oncolytics Owen Blaschak LifeSci Communications oblaschak@
National Post
5 hours ago
- National Post
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference
Article content VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG) ('Alpha Cognition' or the 'Company'), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will share the following poster presentations: Article content Bioequivalence of ZUNVEYL Article content Article content , a Galantamine Prodrug to Galantamine Hydrobromide Extended-Release Demonstrated Under Article content Steady State Article content Conditions (Poster #107147) – July 27 Article content Bioequivalence of ZUNVEYL Article content , a Galantamine Prodrug to Galantamine Hydrobromide Immediate-Release Demonstrated Under Article content Fed and Fasting Conditions Article content (Poster#107030) – July 28 Article content , a Galantamine Prodrug, Over a Dosage Range of Five to Fifteen Milligrams Demonstrated Under Fasting Conditions (Poster #107255) -July 30 Article content 'We are excited to present data demonstrating ZUNVEYL's bioequivalence and dose proportionality,' said Dr. Denis Kay, Chief Scientific Officer of Alpha Cognition. 'Given the high unmet need and challenges with current treatments, ZUNVEYL has the potential to offer physicians a well-tolerated therapy with compelling clinical benefits.' Article content AAIC is the world's largest forum for dementia research, convening global leaders in basic and clinical science to advance prevention, diagnosis, and treatment of Alzheimer's disease. Article content About Alpha Cognition Inc. Article content Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options. Article content ALPHA-1062 formulated as a delayed release oral tablet (ZUNVEYL), is an FDA approved new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as a sublingual formulation for cognitive Impairment with mTBI. Article content ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. Article content IMPORTANT SAFETY INFORMATION Article content CONTRAINDICATIONS Article content ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred. Article content WARNINGS AND PRECAUTIONS Article content Serious Skin Reactions Article content : Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered. Article content Anesthesia Article content Cardiovascular Conditions: Article content Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction. Article content Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope. Article content Gastrointestinal Conditions Article content : Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding. Article content Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL. Article content Genitourinary Conditions: Article content Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction. Article content Neurological Conditions: Article content Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL. Article content Pulmonary Conditions: Article content Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions. Article content ADVERSE REACTIONS Article content The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. Article content DRUG INTERACTIONS Article content Use with Anticholinergics: Article content Galantamine has the potential to interfere with the activity of anticholinergic medications. Article content Use with Cholinomimetics and Other Cholinesterase Inhibitors: Article content A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. Article content USE IN SPECIFIC POPULATIONS Article content Pregnancy: Article content Based on animal data may cause fetal harm. Article content Hepatic Impairment: Article content In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended. Article content Renal Impairment: Article content In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended. Article content These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information. Article content Forward-looking Statements Article content This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the, the long-term benefits of ZUNVEYL, the Company's timing and planned activities and business strategy to launch ZUNVEYL, the potential timing for the availability of ZUNVEYL, the potential future developments of ZUNVEYL, the market size and demand for ZUNVEYL and the Company's potential growth opportunities, capital requirements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks related to our focus on the long-term care market, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's Form S-1/A registration statement as filed with the SEC on January 10, 2025 and available at These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Article content Article content Article content
